ReviewAntiviral therapy2012
Transfusion transmission of HCV, a long but successful road map to safety.
Review in Antiviral therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Prevalence and trends of hepatitis B and C virus biomarkers in Zimbabwe: comparative analyses of a nation's blood-donor surveillance data and meta-analyses of population studies.Infectious diseases (London, England) · 2024Pooled it
- Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units.The Cochrane database of systematic reviews · 2016Pooled it
- Prevalence of Viral Hepatitis in Three Public Health Clinics in the Kingston Metropolitan Area, Jamaica, 2022.The American journal of tropical medicine and hygiene · 2026Article
- Epidemiology and Risk Factors for HCV Infection Among MSM With or at Risk of HIV in Madrid (2022-2024).Open forum infectious diseases · 2025Article
- Socioeconomic determinants of malaria and hepatitis infections: insights from the Federal Medical Center, Makurdi, North Central, Nigeria.BMC public health · 2024Article
- Hepatitis C Virus Elimination in the United States: Challenges, Progress, and Future Steps.Gastroenterology & hepatology · 2023Article
- CMV, B and C hepatitis among multi-transfused hereditary hemolytic Anemia children: an updated Egyptian experience.Italian journal of pediatrics · 2021Article
- Path from the discovery to the elimination of hepatitis C virus: Honoring the winners of the Nobel Prize in Physiology or Medicine 2020.The Kaohsiung journal of medical sciences · 2021Review
- Genotyping & diagnostic methods for hepatitis C virus: A need of low-resource countries.The Indian journal of medical research · 2018Review
- Role of Serologic and Molecular Diagnostic Assays in Identification and Management of Hepatitis C Virus Infection.Journal of clinical microbiology · 2016Review
- One size will never fit all: the future of research in pediatric transfusion medicine.Pediatric research · 2014Review
- Acute hepatitis C: management in the rapidly evolving world of HCV.Current gastroenterology reports · 2014Review
- Clinicoepidemiology and Diagnosis of Hepatitis C: Evaluating HCV Core Antigen Assay as a Diagnostic Tool in a Tertiary Care Teaching Hospital of North India.Euroasian journal of hepato-gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
Improved blood banking practices and the development and implementation of increasingly sensitive serological and nucleic acid amplification technology assays for screening donors for HCV over the past few decades have helped minimize the residual risk from transfusion transmitted HCV in the developed world. Furthermore, studies of transfusion transmitted infections and of donors identified as infected by routine screening have provided significant insights into HCV transmission, epidemiology and pathogenesis. However, transfusion transmission of HCV is still a significant route of infection in the developing world. Key preventive mechanisms to ensure safe blood include elimination of paid donors and development of national donor pools comprising volunteer repeat blood donors, combined with implementation of standardized and maximally sensitive screening assays for HCV. There is also a need to develop up-to-date data on HCV disease burden on a global scale, in part, derived from systematic screening of donors for HCV infection. We suggest the creation of blood donor databases and specimen repositories, both at national and international levels, to facilitate epidemiological surveillance and pathogenesis and treatment studies in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.